World and Chinese Monoclonal Antibody Industry Report to 2013 – ReportsnReports

2013-02-01
Published : Feb-2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the global monoclonal antibody market scale will reach USD78 billion in 2012. Meanwhile, monoclonal antibody is also a key major source of blockbuster drugs. In 2011, the sales of six monoclonal antibody agents as Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (Abbvie) and Trastuzumab (Roche) reached above USD5 billion around the globe, approximating 60% of global monoclonal antibody market.

Due to the features as high technical threshold, large capital demand and high rate of return, the international pharmaceutical giants (including Roche, Johnson & Johnson, Abbvie, Amgen, Novartis, etc.) are still accelerating the research and industrialization of monoclonal antibody agents through M&A or cooperation on the basis of existing monoclonal antibody products. For example, in April 2012, Amgen and AstraZeneca announced that they would jointly develop and sell the 5 monoclonal antibody agents of Amgen under research, namely, AMG827, AMG139, AMG181, AMG557 and AMG157.

Although the monoclonal antibody has witnessed rapid development, and the market scale is expected to share 8%-10% of world’s total in 2012, the market in China is still mainly occupied by imported products. As of the end of 2012, the number of imported monoclonal antibody products approved by SFDA amounted to 11, while that of domestic-made products only reached 8; the number of imported monoclonal antibody agents approved for clinical tests in China amounted to 27, while the figure of domestic products only hit 20, mainly imitating the overseas original drugs.

At present, the imported products as Rituximab, Trastuzumab, Cetuximab, Infliximab and Bevacizumab have contributed 70%-75% of monoclonal antibody market in China; the rest market is shared by the home-made drugs as Yisaipu®（Recombinant Human TNF Receptor-Ig Fusion Protein）and Xenopax® （Recombinant Humanized Anti-CD25 Monoclonal Antibody）of CPGJ, and Nimotuzomab of Biotech Pharma. Besides, several imported monoclonal antibody agents have accessed some local medical insurance systems. For example, Remicade®（Infliximab）, which is used to treat rheumatoid, has accessed 11 local medical insurances, Simulect® (Bevacizumab, used in anti-transplant rejection) has accessed 10 local medical insurances, and Rituxan® (Rituximab, used to treat tumors) has accessed 9 local medical insurances. Meanwhile, since it may take 3-5 years for the domestic-made monoclonal antibody agents to achieve large scale and industrialized marketing, the imported markets will still embrace expectable development in future.

In view of the optimistic market prospect, advancement of monoclonal antibody technologies, support of favorable policies and the upcoming patent expiration of several key monoclonal antibody agents, multiple local enterprises as Hisun Pharmaceutical, Fosun Pharmaceutical, Walvax Biotechnology and SL Pharmaceutical are now marching into the monoclonal antibody market by huge capitals successively.

As of December 2012, the first monoclonal antibody generic drug (generic drug of enbrel) – Anbainuo® of Hisun Pharmaceutical was under phase III clinical supplementary test, and is expected to be approved by the end of 2013. The commercialized capacity will be 3.2 million pieces per year; furthermore, Enbrel has been tested in Brazil, etc., and is expected to achieve export.

In July 2012, the environmental impact assessment concerning phase I of new medicine pilot test base project (monoclonal antibody agents) of Fosun Pharmaceutical was publicized. According to the notice, the pilot scale of the project will be 130kg/a (equal to 1.3 million pcs/a of Rituximab), and the construction content involves raw material storage, pilot workshop, quality inspection, administration building and supporting public auxiliary facilities.

In April 2012, Walvax Biotechnology announced to jointly sign Cooperation Framework Agreement with Shanghai Fengmao Biotechnology, Shanghai Winlord Industries & Trading, and natural persons Wang Xiaofei and Kong Haiyan, planning to invest in Shanghai Fengmao in future four years, and research and industrialize Rituximab, Bevacizumab, Adalimumab, Panitumumab, Denosumab and long-acting EPO; in August, the company invested RMB246 million to establish the fully-owned subsidiary Shanghai Walvax, so as to promote the industrialization of the above six blockbuster bio-similar products. Nevertheless, according to the public information, the monoclonal antibody generic drugs of Walvax Biotechnology cannot be marketed until 2017 (Rituximab and Panitumumab as planned), and the commodity volume is expected to be 12kg/a, sharing 10% of planned capacity.

Request a sample before buying a copy of this report @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=218305.

Global and China Monoclonal Antibody Industry Report, 2013 of ResearchInChina mainly involves the following contents:

Development status, market scale, competitive pattern and development forecast, etc. of monoclonal antibody industry around the globe;
Development status, market scale, competitive pattern and development forecast, etc. of monoclonal antibody industry in China;
Operation, monoclonal antibody business, development in China, R&D status, etc. of 6 monoclonal antibody enterprises around the globe and 10 enterprises in China.

Buy a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=218305.

Contact [email protected] for further information.

Filed in: Biotechnology
Tags: 
More Reports
Title Price Buy Now

Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User – Global Forecast to 2027

“The stem cell assays market growth can be attributed to factors such as the rising demand for technologically advanced stem cell analysis instruments, increase in the prevalence of cancer & other diseases and rising number of biopharma and & biotechnology companies working on stem cell based therapies.” The stem cell assays market is projected to reach USD 4.5 Billion by 2027 from USD 1.9 Billion in 2022, at a CAGR of 17.7% during the forecast period. The growth of the market is projected to be driven by collaborations and agreements among market players for stem cell assay products & services, launch of new stem cell analysis systems such as flow cytometers and increase in R&D expenditure by biopharmaceutical and biotechnology companies. The viability/cytotoxici......
 $

Nucleic Acid Isolation & Purification Market by Product (Kit, Reagent, Instrument), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, miRNA), Application (Drug Discovery, Diagnostics), End User (Pharma, Biotech) – Global Forecast to 2027

The nucleic acid isolation and purification market is expected to grow at a CAGR of 7.9% in the forecast period. The global nucleic acid isolation and purification market is projected to reach USD 9.2 billion by 2027 from USD 6.3 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth of this market can majorly be attributed to the increasing R&D activities as well as technological advancements and increasing automation. The emerging economies, improving regulatory and reimbursement scenario, and the growing adoption of molecular diagnostics and personalized medicines are expected to offer a wide range of growth opportunities for players in the market. However, the high cost of automated instruments is expected to hinder the growth of the market. As the world be......
 $4950

Wound Care Biologics Market by Product (Biological Skin Substitutes, Topical Agents), Wound Type (Ulcers [Diabetic Foot, Venous, Pressure Ulcers], Surgical & Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers) – Global Forecast to 2027

“Rising number of road accidents and associated traumatic wounds and growing incidence of burn injuries are driving the overall growth of the wound care biologics market” The global wound care biologics market is valued at an estimated USD 1.8 billion in 2022 and is projected to reach USD 2.4 billion by 2027, at a CAGR of 5.4% during the forecast period. Market growth is driven by factors such as the growing incidence of burn injuries and the rising number of road accidents and associated traumatic wounds. However, the high cost of wound care biologic products and the risk associated with skin substitute failure are the major factors hampering the growth of this market. “The biological skin substitutes segment accounted for the highest growth rate in the wound care biologics ma......
 $4950

Bioanalytical Testing Services Market by Type, Application (Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology), End User and Region (North America, Europe, APAC, Latin America, MEA) – Global Forecast to 2027

“The global bioanalytical testing services market is projected to grow at a CAGR of 15.6%” Bioanalytical testing involves analytical methods used for the detailed examination of biological and biotechnology products. Bioanalysis enables the quantitative measurement of drugs and their metabolites, biological molecules in unnatural locations or concentrations, DNA, and large molecules. The global bioanalytical testing services market is projected to reach USD 6.0 billion by 2027 from an estimated USD 2.9 billion in 2022, at a CAGR of 15.6% during the forecast period. “The Cell-based assays segment is expected to account for the largest share of the bioanalytical testing services market” The increasing prevalence of chronic diseases and the rising number of clinical trials ar......
 $4950

Cell Analysis Market by Product & Service (Reagents & Consumables, Instruments), Technique (Flow Cytometry, High Content Screening), Process (Single-cell Analysis), End User (Pharmaceutical and Biotechnology Companies) – Global Forecast to 2027

“Single-cell analysis segment has gained significant traction in the recent years attributed to the widening applications of this technology in cancer research. This is further supplemented by the robust government initiatives targeted towards single-cell analysis research. The growth of the single-cell analysis segment is expected to drive the overall growth of the cell analysis market.” The global cell analysis market is projected to reach USD 28.6 Billion by 2027 from USD 17.7 Billion in 2022, at a CAGR of 10.1% during the forecast period. Key opportunities for the cell analysis market include, emerging economies, high risk of communicable diseases and pandemic outbreak, and increasing adoption of novel cellular assays in various cancer research applications. On the other hand, h......
 $4950

3D Cell Culture Market by Type (Hydrogel, ECM, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation), Application (Cancer, Stem Cell, Toxicology, Tissue Engineering), End User (Pharma, Biotech, Research, Cosmetics), Region – Global Forecast to 2027

“Increasing focus on developing alternative methods to animal testing, growing focus on personalized medicine is driving the overall growth of the3D Cell culture market” The global 3D cell culture market is valued at an estimated USD 1.3 billion in 2022 and is projected to reach USD 2.6 billion by 2027, at a CAGR of 15.6% during the forecast period. The growth of this market is mainly driven by factors such as the increasing focus on developing alternative methods to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, a lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth of this market during the f......
 $4950

Tangential Flow Filtration Market by Product (System, Membrane Filter), Material (PES, PVDF, PTFE), Technique (Ultrafiltration), Application (Final Product Processing, Raw Material Filtration), End User (Pharma, Biotech), Region – Global Forecast to 2027

“Growth in the tangential flow filtration market can be attributed to factors such as the growing advantages of tangential flow filtration over normal flow filtration, rising R&D spending in pharmaceutical & biotechnology industries and increasing adoption of single-use technologies.” The global tangential flow filtration market is projected to USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 13.2% during the forecast period. The rising advantages of tangential flow filtration over normal flow filtration, increasing adoption of single-use technologies, and growing R&D spending in pharma-biotech companies. On the contrary, the high capital investments for setting up new production facilities are expected to restrain the market growth. “In 2021 the s......
 $4950

Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) – Global Forecast to 2029

“Increased focus on human microbiome therapy development to drive the growth of this market.” The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029. The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth. “By product segment, the drugs segment accounted for the largest share of huma......
 $4950

Exosome Research Market by Product and services (Kits, Reagents, Instrument), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem cell, Dendritic cell-derived), End User – Global Forecast to 2026

“Increasing interest in exosome-based proceduresto Drive the Growth of Market” The exosome research market is valued at an estimated USD 144 million in 2021 and is projected to reach USD 661 million by 2026, at a CAGR of 35.6% during the forecast period, owing to increased funding for life sciences research, the high global prevalence of cancer, and the increasing interest in exosome-based procedures. “By product & service, the kits & reagents segment accounted for the largest share of the exosome research market” Based on product and service, the exosomes market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is further divided into antibodies, isolation, purification, quantitation kits & reagents, and other ki......
 $4950

Metagenomic Sequencing Market by Product & Services (Reagent, Consumables, Instrument), Workflow (Sample Preparation, Sequencing), Technology (16S rRNA, Shotgun, Whole-genome), Application (Drug Discovery, Diagnostic) – Global Forecast to 2027

“Continuous technological innovations in NGS platforms is the key factors driving growth in the metagenomic sequencing market’’ The metagenomic sequencing market is expected to reach USD 4.3 billion by 2027 from USD 1.9 billion in 2022, at a CAGR of 18.4% during the forecast period. Growth in the metagenomic sequencing market is mainly driven by continuous technological innovations in NGS platforms, increasing initiatives and funding from government & private bodies for large-scale sequencing projects, declining costs of genome sequencing, and the significant applications of metagenomics in various fields. “By technology segment, the shotgun metagenomic sequencing segment accounted for the fastest-growing segment of the metagenomic sequencing market” Based on technol......
 $4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy